Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M306363200 on September 18, 2003

J. Biol. Chem., Vol. 278, Issue 47, 47232-47239, November 21, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/47/47232    most recent
M306363200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jia, Y.
Right arrow Articles by Reddy, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jia, Y.
Right arrow Articles by Reddy, J. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Overexpression of Peroxisome Proliferator-activated Receptor-{alpha} (PPAR{alpha})-regulated Genes in Liver in the Absence of Peroxisome Proliferation in Mice Deficient in both L- and D-Forms of Enoyl-CoA Hydratase/Dehydrogenase Enzymes of Peroxisomal {beta}-Oxidation System*

Yuzhi Jia{ddagger}, Chao Qi{ddagger}, Zhongyi Zhang{ddagger}, Takashi Hashimoto{ddagger}, M. Sambasiva Rao{ddagger}, Steven Huyghe§, Yasuyuki Suzuki¶, Paul P. Van Veldhoven§, Myriam Baes§, and Janardan K. Reddy{ddagger}||

From the {ddagger}Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611-3008, the §Laboratory of Clinical Chemistry, Faculty of Pharmaceutical Sciences, K.U. Leuven, Herestraat 490/N B3000 Leuven, Belgium, and The Department of Pediatrics, Gifu University School of Medicine, 40 Tsukasa-machi, Gifu 500, Japan

Received for publication, June 16, 2003 , and in revised form, August 7, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Peroxisomal {beta}-oxidation system consists of peroxisome proliferator-activated receptor {alpha} (PPAR{alpha})-inducible pathway capable of catalyzing straight-chain acyl-CoAs and a second noninducible pathway catalyzing the oxidation of 2-methyl-branched fatty acyl-CoAs. Disruption of the inducible {beta}-oxidation pathway in mice at the level of fatty acyl-CoA oxidase (AOX), the first and rate-limiting enzyme, results in spontaneous peroxisome proliferation and sustained activation of PPAR{alpha}, leading to the development of liver tumors, whereas disruptions at the level of the second enzyme of this classical pathway or of the noninducible system had no such discernible effects. We now show that mice with complete inactivation of peroxisomal {beta}-oxidation at the level of the second enzyme, enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase (L-PBE) of the inducible pathway and D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase (D-PBE) of the noninducible pathway (L-PBE-/-D-PBE-/-), exhibit severe growth retardation and postnatal mortality with none surviving beyond weaning. L-PBE-/-D-PBE-/- mice that survived exceptionally beyond the age of 3 weeks exhibited overexpression of PPAR{alpha}-regulated genes in liver, despite the absence of morphological evidence of hepatic peroxisome proliferation. These studies establish that peroxisome proliferation in rodent liver is highly correlatable with the induction mostly of the L- and D-PBE genes. We conclude that disruption of peroxisomal fatty acid {beta}-oxidation at the level of second enzyme in mice leads to the induction of many of the PPAR{alpha} target genes independently of peroxisome proliferation in hepatocytes, raising the possibility that intermediate metabolites of very long-chain fatty acids and peroxisomal {beta}-oxidation act as ligands for PPAR{alpha}


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
In mammals, fatty acid oxidation occurs in mitochondria, peroxisomes, and smooth endoplasmic reticulum (1). Whereas mitochondria and peroxisomes oxidize fatty acids via {beta}-oxidation, the cytochrome P450 CYP4A subfamily of enzymes located in the smooth endoplasmic reticulum metabolizes fatty acids by {omega}-oxidation (1–3). Mitochondrial {beta}-oxidation is responsible for the oxidation of the major portion of the short-(<C8), medium-(C8–C12), and long-(C14–C20) chain fatty acids and, in the process, constitutes the primary source of energy derived from fatty acids. On the other hand, peroxisomal {beta}-oxidation is responsible for the metabolism, almost exclusively, of very long straight-chain fatty acids (>C20), 2-methyl-branched fatty acids (e.g. pristanic acid that is generated after {alpha}-oxidation of the 3-methyl-branched fatty acid phytanic acid), prostanoids, dicarboxylic acids, and the C27 bile acid intermediates di- and trihydroxycoprostanoic acids (1, 2, 4). The importance of peroxisomes and peroxisomal fatty acid {beta}-oxidation for human health is underscored by the existence of peroxisomal biogenesis disorders such as Zellweger syndrome and other genetic diseases affecting peroxisomal {beta}-oxidation (1, 2) and by the ability of many structurally diverse chemicals designated as peroxisome proliferators to induce peroxisome proliferation and increase fatty acid oxidation in liver cells, leading to the development of liver tumors in rodents (5–7).

Peroxisomal {beta}-oxidation consists of four steps. Each metabolic conversion can be carried out by at least two different enzymes. The classical peroxisome proliferator-inducible pathway utilizes straight-chain acyl-CoA as substrates, whereas the second noninducible pathway catalyzes the oxidation of 2-methyl-branched fatty acyl-CoAs (1, 2, 4). In the classical inducible {beta}-oxidation pathway, dehydrogenation of acyl-CoA esters to their corresponding trans-2-enoyl-CoAs is catalyzed by fatty acyl-CoA oxidase (AOX),1 whereas the second and third reactions, hydration and dehydrogenation of enoyl-CoA esters to 3-ketoacyl-CoA, are catalyzed by a single enzyme, enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase (L-bi-/multifunctional enzyme (L-PBE/MFP1)) (1, 2, 4). The third enzyme of this inducible system, 3-ketoacyl-CoA thiolase (PTL), converts 3-ketoacyl-CoA to acetyl-CoA and an acyl-CoA that is two carbon atoms shorter than the original molecule, and the shortened acyl-CoA re-enters the {beta}-oxidation cycle (1, 2, 4). In the noninducible {beta}-oxidation pathway, dehydrogenation of branched fatty acyl-CoA esters to their corresponding trans-2-enoyl-CoAs is catalyzed by the branched chain acyl-CoA oxidase or by pristanoyl-CoA oxidase (4). These enzymes are also capable of desaturating straight-chain acyl-CoAs. The second and third reactions of this pathway are performed by D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase (D-bi/multifunctional enzyme (D-PBE/MFP2)), and the resulting 3-ketoacyl-CoAs are cleaved by the third enzyme of this system, designated sterol carrier protein x (SCPx), which possesses thiolase activity (4, 8). The gene encoding SCPx, a 58-kDa protein with 3-ketoacyl-CoA thiolase activity, also codes for a smaller 5.3-kDa protein designated sterol carrier protein 2 (SCP2 or nonspecific lipid transfer protein) (4, 8). The three enzymes of the classical {beta}-oxidation pathway are markedly induced in conjunction with peroxisome proliferation by peroxisome proliferators (9). These agents exert their pleiotropic effects in liver by activating a nuclear receptor designated as peroxisome proliferator-activated receptor {alpha} (PPAR{alpha}) (10). The PPAR subfamily consists of three members, {alpha}, {beta}/{delta}, and {gamma} (11), that heterodimerize with retinoid X receptor (12), and the PPAR/retinoid X receptor complex binds to peroxisome proliferator-response element, a region consisting of a degenerate direct repeat of the canonical AGGTCA sequence separated by 1 base pair (DR1), present in the 5'-flanking region of target genes (12, 13). Sustained activation of PPAR{alpha} in liver by these synthetic ligands in rats and mice leads to the development of liver tumors (7, 14). Activation of PPAR{alpha} by natural ligands in the liver of AOX-/- mice also leads to the development of liver cancer (15). In this sense, the functional integrity of the classical {beta}-oxidation pathway at the level of the first enzyme AOX appears to be essential to keep PPAR{alpha} in check and prevent spontaneous peroxisome proliferation by effectively metabolizing AOX substrates, which appear to function as natural PPAR{alpha} ligands (15). Disruption of the gene encoding L-PBE, the second enzyme of this classical system, did not manifest either in spontaneous peroxisome proliferation or in the transcriptional activation of PPAR{alpha} target genes in liver, indicating that inactivation of classical {beta}-oxidation system distal to AOX step does not interfere with the inactivation of endogenous ligands of PPAR{alpha} (15, 16). The absence of appreciable defects in lipid metabolism in L-PBE-/- mice suggested that enoyl-CoAs, generated in the classical {beta}-oxidation system, are diverted to the noninducible branched chain {beta}-oxidation pathway for degradation by D-PBE (16). In this study, to investigate the functional implications of the disruption of the metabolism of enoyl-CoAs on lipid metabolism, peroxisome proliferation, and PPAR{alpha} activation in liver, we generated mice deficient in both L-PBE and D-PBE enzymes so that both peroxisomal {beta}-oxidation pathways are effectively disrupted at the second enzyme level. Mice deficient in both L-PBE and D-PBE enzymes (L-PBE-/-D-PBE-/-) exhibited severe growth retardation and postnatal mortality. They revealed microvesicular hepatic steatosis, abnormalities in mitochondrial structure, and overexpression of PPAR{alpha}-regulated genes in liver, despite the lack of morphological evidence of peroxisome proliferation. These findings establish that the induction of many of the PPAR{alpha} target genes can occur independently of peroxisome proliferation, further extending previous results (16), and that peroxisome proliferation in rodent liver is highly correlatable with the induction mostly of the L-PBE gene.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Generation of L-PBE-/-D-PBE-/-Mice—The generation of AOX-/-, L-PBE, and D-PBE (MFP-2) null mice has been described elsewhere (16–18). Since D-PBE deficiency resulted in reduced fertility of D-PBE-/- mice (18), L-PBE-/- mice were mated with heterozygous D-PBE+/- mice to obtain L-PBE+/-D-PBE+/- mice. These were intercrossed to generate L-PBE+/+D-PBE+/- and L-PBE-/-D-PBE+/- mice. The L-PBE-/-D-PBE+/- mouse lineages were used to generate L-PBE+/+D-PBE-/-, and L-PBE-/-D-PBE-/- double knockout (DKO) mice. DNA extracted from the tail tips of mice and from the yolk sac of embryos was used for genotyping as described elsewhere (16, 18). All animal procedures used in this study were approved by the Institutional Review Board for Animal Research of the Northwestern University.

Morphological Analysis, Catalase Cytochemistry, and AOX and L-PBE Immunohistochemistry—Wild-type (C57BL/6J), L-PBE-/-, and D-PBE-/- mice, 6–8 weeks of age, were fed powdered diet with or without Wy-14,643 (0.0125% w/w), a peroxisome proliferator (5), for 2 weeks. L-PBE-/- D-PBE-/- mice were with the dams that were maintained on a normal diet without Wy-14,643. AOX-/- mice were also on a normal diet without the drug. For light microscopy, tissues were fixed in 10% neutral buffered formalin and embedded in paraffin. Histological analysis was performed using 4-µm-thick sections stained with hematoxylin and eosin. For cytochemical localization of catalase (CTL), the peroxisomal marker enzyme, tissues were incubated in alkaline 3,3-diaminobenzidine reaction mixture and processed for light and electron microscopy as described (15, 17). Immunohistochemical localization of AOX and L-PBE proteins in liver fixed in 10% formalin or 70% ethanol was performed using monospecific polyclonal antibodies as described (16, 17).

Northern Analysis—Total RNA extracted from liver with TRIzol reagent (Invitrogen) was glyoxylated, separated on 0.8% agarose gel, transferred to nylon membrane, and then hybridized at 42 °C in 50% formamide hybridization solution using 32P-labeled cDNA probes as described (17, 19). Changes in mRNA levels were estimated by densitometric scanning of autoradiograms.

SDS-PAGE Analysis and Immunoblotting—Liver homogenates were separated by SDS-PAGE and stained with Coomassie Brilliant R Blue for assessing the induction of 78-kDa protein, which represents L-PBE, and was initially identified as peroxisome proliferation-associated polypeptide (20). Contents of {beta}-oxidation enzymes AOX, L-PBE, D-PBE, PTL, and sterol carrier protein (SCPx) and of peroxisomal CTL and urate oxidase (UOX) in liver were determined by immunoblot analysis as described (16, 21, 22).

Fatty Acid Analysis—Serum was stored at -20 °C until analysis. Sample preparation and analysis were according to the procedures described (23).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Growth Retardation and Postnatal Mortality in L-PBE-/-D-PBE-/- Mice—L-PBE-/- (16) and D-PBE-/- (18) mice were crossbred to generate mice nullizygous for both L-PBE and D-PBE (L-PBE-/-D-PBE-/-) (Fig. 1A). Genotype analysis performed on litters during the late gestational age (embryonic day 17.5) or on postnatal day 1 revealed the expected Mendelian ratios from L-PBE-/-D-PBE+/- animals, suggesting no intrauterine mortality (data not shown). L-PBE-/-D-PBE-/- DKO litter revealed variable but striking growth retardation at birth as compared with L-PBE-/-D-PBE+/- and L-PBE-/-D-PBE+/+ littermates. Mice deficient in both L-PBE and D-PBE that died during the first 3 postnatal days were grossly undersized, underweight, and hypotonic with difficulties in suckling as evidenced by the reduced quantity of milk in their stomach. Some of the DKO mice that were stronger appeared to suckle adequately but showed marked retardation in weight gain and growth rate (Fig. 1B). Almost all of the L-PBE and D-PBE double null mice died before weaning, and a rare animal (<10% of double nulls) that survived up to 5 weeks was still with the dam suckling and did not consume solid diet. As described previously, mating of L-PBE+/- mice yielded L-PBE-/- mice with the expected Mendelian inheritance ratio of 25%; likewise, mating of D-PBE+/- mice also generated D-PBE-/- mice at the expected ratio of ~25%, and these single nulls were indistinguishable at birth from their heterozygous and wild-type littermates (16, 18). No detectable phenotype was noted in L-PBE-/- mice, which were viable and fertile (16), whereas, 30% of the D-PBE-/- mice died before postnatal day 12, and most of the remaining mice survived to adulthood (18). Thus, the failure of L-PBE-/- D-PBE-/- mice to survive beyond 5 weeks of age is considered a reflection of the consequences of the total disruption of two {beta}-oxidation pathways to metabolize the enoyl-CoAs generated by the first step of the peroxisomal {beta}-oxidation cycle catalyzed by acyl-CoA oxidases (1). Increases in C26:0 (3.5-fold) and phytanic acid (4-fold) levels were noted in the serum of L-PBE-/-D-PBE-/- mice. A 7-fold increase in C26:0/C22:0 was noted in L-PBE-/-D-PBE-/- mice, as compared with wild-type mice. There was also a significant decrease in docosahexaenoic acid level (3.5-fold) in the serum of these double knockout mice. These observations indicate that in DKO mice, peroxisomal {beta}-oxidation is abnormal.



View larger version (118K):
[in this window]
[in a new window]
  		FIG. 1.
L-PBE-/-D-PBE-/- mice. A, Southern blot analysis of genomic DNA for L-PBE and D-PBE gene deletion. B, retarded growth and hypotonia in 3.5-week-old L-PBE and D-PBE double null mouse (upper) as compared with wild-type (lower) littermate.

 
Characterization of Liver Phenotype in L-PBE-/-D-PBE-/- Mice That Survived beyond the Age of 3 Weeks—The histological architecture of liver and the morphologic appearance of hepatocytes in mice deficient in either L-PBE or D-PBE did not differ significantly from each other or from that of wild-type animals during the first 5 weeks of their postnatal development (Fig. 2, A–C). In contrast, the liver of mice deficient in both L-PBE and D-PBE revealed a mild degree of microvesicular fatty change between 3 and 5 weeks of age (Fig. 2D). The hepatic steatosis observed in L-PBE-/- D-PBE-/- mice was considerably less pronounced as compared with that noted in AOX-/- mice (15, 17). Survey for alterations in peroxisome population in liver cells of L-PBE-/-D-PBE-/- mice using 0.5-µm-thick liver sections that were processed using the alkaline 3,3-diaminobenzidine cytochemical method to visualize peroxisomal marker enzyme catalase (15) revealed similar peroxisome density and numerical distribution in mice deficient in either L-PBE (Fig. 2F) or D-PBE (Fig. 2G) as compared with wild type (Fig. 2E). In contrast, L-PBE and D-PBE double knockout mouse livers did not reveal the presence of discrete brown dots in the hepatocyte cytoplasm that represent peroxisomes (Fig. 2H). The hepatocyte cytoplasm and nuclei exhibited a diffuse brown reaction, suggesting the presence of soluble catalase in these locations instead of in the expected peroxisomal compartment.



View larger version (133K):
[in this window]
[in a new window]
  		FIG. 2.
Liver morphology in L-PBE-/-D-PBE-/-double null mice. A–D, liver sections stained with hematoxylin and eosin. E–H, sections of liver that were processed for the cytochemical localization peroxisomal catalase. A and E, wild type; B and F, L-PBE-/-; C and G, D-PBE-/-; and D and H, L-PBE-/-D-PBE-/- mice.

 
At the ultrastructural level, peroxisomes in hepatocytes of wild-type mouse livers appeared as discrete single membrane limited particles with dense osmiophilic material in sections that were processed for the localization of catalase (Fig. 3A). Similar distribution of peroxisomes was also noted in L-PBE-/- or D-PBE-/- mouse livers (not illustrated). In contrast, the liver cells of mice deficient in both L-PBE and D-PBE revealed a marked reduction in peroxisome population, and when present, they were seen as microperoxisomes (Fig. 3B). Liver cells in DKO mice also revealed severe abnormalities in the appearance of mitochondrial structure (Fig. 3B). The mitochondrial abnormalities include condensations with curvilinear alterations of cristae, myelin-like rings, evaginations and invaginations of the outer membrane, and an occasional mitochondrial ghost. Microvesicular steatosis is also seen in the cytoplasm. Defects in mitochondrial structure have also been described in Zellweger syndrome patients and in mouse models of defective peroxisomal biogenesis (24).



View larger version (129K):
[in this window]
[in a new window]
  		FIG. 3.
Peroxisomal and motochondrial changes in L-PBE-/-D-PBE-/-double null mice. Electron micrographs of liver cells that were processed for the cytochemical localization of peroxisomal catalase from wild-type (A) and L-PBE-/-D-PBE-/-double null mice (B) are shown. Note the paucity of diaminobenzidine-stained peroxisomes (P) in the L-PBE-/-D-PBE-/- double null mouse liver cells.

 
Up-regulation of PPAR{alpha} Target Gene Expression in the Absence of Peroxisome Proliferation—Previously, we demonstrated that mice deficient in AOX, the first and rate-limiting enzyme of the inducible classical peroxisomal {beta}-oxidation system, exhibit spontaneous peroxisome proliferation and transcriptional activation of PPAR{alpha} target genes in liver (15). These observations indicated that AOX substrates that remain unmetabolized by the branched-chain oxidase function as natural ligands of PPAR{alpha}, leading to sustained activation of this receptor (15, 25). Because no such changes occurred in the livers of mice deficient in L-PBE, the second enzyme of this inducible {beta}-oxidation system, it appeared that D-PBE, the second enzyme of the noninducible peroxisomal {beta}-oxidation pathway, would metabolize the substrates of L-PBE (16). The disruption of both L-PBE and D-PBE genes in the present study provided an opportunity to examine whether the induction of PPAR{alpha} target genes occurs in liver when the two {beta}-oxidation pathways are interrupted at the level of the second enzyme, although there was no morphological evidence of spontaneous peroxisome proliferation (Fig. 2H). Northern analysis of liver RNA obtained from 4-week-old animals for changes in the levels of PPAR{alpha}-regulated fatty acid oxidation system genes, namely AOX, L-PBE, PTL, CYP4A1, and CYP4A3, revealed marked increases in the mRNA levels of AOX, PTL, CYP4A1, and CYP4A3 in L-PBE-/-D-PBE-/- mice with the expected absence of L-PBE and D-PBE mRNAs due to the gene disruption (Fig. 4A). We noted marked increase in the mRNA content of Riken clone W09719 [GenBank] in earlier cDNA microarrays, which was identified as a PPAR{alpha}-regulated gene in liver (19, 26). Recently, this Riken clone W09719 [GenBank] has been found identical to SCP2/SCPx (27, 28), encoding for the second thiolase enzyme (1–4). Increase in hepatic SCP2/SCPx mRNA level indicates (Fig. 4B) that this gene, like AOX, L-PBE, and PTL, is also regulated by PPAR{alpha}. Modest increases in liver fatty acyl-CoA synthetase and fatty acid synthetase mRNA levels were noted in L-PBE-/-D-PBE-/- and AOX-/- mice (Fig. 4A). These results strongly suggest spontaneous up-regulation of PPAR{alpha} target gene expression in liver in double knockout mice, similar to that seen in AOX-/- livers (Fig. 4A). It is of interest to note that modest increases in the mRNA levels of ACTE, PEX11{alpha}, and PMP70 also occurred in the L-PBE-/-D-PBE-/- and AOX-/- mouse livers. As expected, no perceptible alterations in UOX and CTL mRNA levels were noted (Fig. 4A). No significant changes in PPAR{alpha} and PPAR{gamma} mRNA levels were detected among various groups except that PPAR{alpha} levels appeared slightly increased in AOX-/- livers (Fig. 4A).



View larger version (75K):
[in this window]
[in a new window]
  		FIG. 4.
Northern analysis to evaluate changes in PPAR{alpha} target gene expression. A, Northern analysis for changes in the expression of genes involved in lipid metabolism and peroxisome biogenesis. Total liver RNA from 4-week-old mice matched wild-type (WT) (lanes 1 and 2), L-PBE-/- (lanes 3, and 4), D-PBE-/- (lanes 5 and 6) and L-and D-PBE double null (DKO) (lanes 7 and 8), and AOX-/- (lanes 9 and 10) mice (two mice for each group). Twenty µg of total RNA was electrophoresed on a 0.8% agarose gel, blotted onto a nylon membrane, and probed with different random-primed 32P-labeled cDNA probes as shown. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used for loading control. Note increases in fatty acyl-CoA synthetase (ACS), fatty acid synthetase (FAS), PTL, CYP4A1, CYP4A3, ACTE, PEX11{alpha}, and PMP70 mRNA levels in L-PBE-/-D-PBE-/- double null (DKO) and AOX-/- mouse livers (boxed). AOX mRNA is absent AOX-/- but up-regulated in DKO liver. L-PBE and D-PBE mRNAs are absent in DKO livers but up-regulated in AOX-/- mouse liver. No changes in peroxisomal UOX and CTL mRNA levels are noted. B, Northern analysis for the changes in the expression of selected nonperoxisomal genes in liver. Total liver RNA (20 µg) from two mice from each group (lanes 1 and 2, wild type; lanes 3 and 4, L-PBE-/-; lanes 5 and 6, D-PBE; lanes 7 and 8, L-PBE-/- D-PBE-/- double null mice (DKO); lanes 9 and 10, AOX-/-; and lanes 11 and 12, wild type treated with Wy-14,643 for 2 weeks) was hybridized with the 32P-labeled cDNA probes CD36, Ly-6D, PDK-4, SHLR, SCP2 (Riken clone W09719 [GenBank] ), mLipase, C3f, and glyceraldehyde 3-phosphate dehydrogenase as shown. The boxed areas in panels A and B represent significant increases in mRNA levels of putative PPAR{alpha} target genes.

 
Northern analysis of the mRNA levels of some of the recently identified PPAR{alpha}-regulated genes in liver, namely CD36, Ly-6D, PDK-4, SHLR, Riken clone W09719 [GenBank] (now identified as SCP2/SCPx), monoglyceride lipase (mLipase), and C3f (19, 26) showed increases in expression in L-PBE-/-D-PBE-/-, and AOX-/- mouse livers and in the livers of wild-type mice treated with Wy-14,643, a synthetic peroxisome proliferator (Fig. 4B). These observations clearly establish that induction of PPAR{alpha} target genes occurs in liver in the absence of peroxisome proliferation in L-PBE-/-D-PBE-/- double null mice. The mRNA expression profiles are similar to that seen in livers with peroxisome proliferation occurring spontaneously as in AOX-/- mouse liver or as a result of induction in wild-type mice fed Wy-14,643 (Fig. 4B). Immunoblot analysis confirmed the absence of L-PBE and D-PBE proteins in L-PBE-/-D-PBE-/- mouse liver and increases in the content of 72-kDa subunit A (but decrease or absence of 51-kDa subunit) of AOX protein (8, 29, 30) and in the amount of PTL (Fig. 5). Also of interest is the marked decrease in the amount of the 40-kDa subunit of SCPx (8) in L-PBE-/-D-PBE-/- mouse liver (Fig. 5), although the SCP2/SCPx mRNA level is markedly elevated (Fig. 4B). Decreases in the amount of AOX subunit B (51 kDa) and of SCPx 40-kDa subunit strongly suggest that these proteins are not properly targeted and packaged in peroxisomes for posttranslational modification (8, 29, 30). Immunoblotting for UOX in liver samples revealed very little of this protein in DKO livers (Fig. 5) despite the presence of UOX mRNA (Fig. 4A). The relative lack of UOX protein in DKO livers is consistent with the paucity of peroxisomes and failure to see distinct peroxisomal UOX cores in these hepatocytes. These observations suggest possible defects in protein import into peroxisomes (31).



View larger version (90K):
[in this window]
[in a new window]
  		FIG. 5.
Immunoblot analysis of liver proteins for changes in peroxisomal {beta}{beta}-oxidation system proteins. Liver proteins (20 µg) from two mice for each group (WT, L-PBE-/-, D-PBE-/-, L-PBE and D-PBE DKO, and AOX-/-) were immunoblotted for peroxisomal {beta}-oxidation system enzymes, AOX, L-PBE, D-PBE, PTL, and SCPx. For peroxisomal UOX and CTL, 20 and 5 µg of liver protein, respectively, was used. UOX signal was barely detectable in L-PBE-/-D-PBE-/- (DKO) mouse liver.

 
Induction of Peroxisome Proliferation Depends upon the Induction of L-PBE Gene, but Peroxisome Proliferation Is Not Required for the Induction of PPAR{alpha} Target Genes—No peroxisome proliferation was observed in the hepatic parenchymal cells of L-PBE-/-D-PBE-/- mice, whereas Northern analysis revealed the activation of PPAR{alpha}-regulated genes similar to that noted in AOX-/- mouse liver and in wild-type mice fed Wy-14,643 (Fig. 4). To further establish the critical role of transcriptional up-regulation of L-PBE in the induction of the phenomenon of peroxisome proliferation, we analyzed the livers of wild type, L-PBE-/-, and D-PBE-/- with and without Wy-14,643-treatment to assess the amount of 78-kDa L-PBE protein (Fig. 6, A and B), which we originally identified as peroxisome proliferation-associated peptide (20). SDS-PAGE and Coomassie Blue staining (Fig. 6A) and immunoblotting (Fig. 6B) revealed a massive amount of L-PBE protein in the liver of Wy-14,643-treated wild-type and D-PBE-/- mice, which correlates well with peroxisome proliferation in liver cells. No appreciable increase in L-PBE protein was seen in the liver of L-PBE-/- mice fed Wy-14,643, as noted previously, and in these livers, the peroxisome proliferation was markedly subdued (16). Comparison of SDS-PAGE and immunoblot patterns revealed increases in L-PBE protein in AOX-/- liver, but no such increase occurred in L-PBE-/- D-PBE-/- double knockout livers (Fig. 6), although both L-PBE-/-D-PBE-/- and AOX-/- mouse livers exhibited induction of PPAR{alpha} target genes on Northern analysis (Fig. 5). Immunohistochemical staining of liver sections using antibodies against L-PBE (Fig. 7, A–D) revealed induction of L-PBE (Fig. 7, B and C) in wild-type mice treated with Wy-14,643 and in AOX-/- (Fig. 7C) mice. The L-PBE immunostaining revealed distinct cytoplasmic granular pattern consistent with peroxisome proliferation. As expected, L-PBE staining was absent in L-PBE-/-D-PBE-/- mouse liver (Fig. 7D). Of interest is that AOX immunostaining (Fig. 7, E–H) showed increased staining of liver cells of wild-type mice fed Wy-14,643 (Fig. 7F) and in L-PBE-/-D-PBE-/- mouse liver (Fig. 7H). The staining in Wy-14,6643-treated wild-type mouse liver is granular (Fig. 7F, inset), whereas in DKO mouse liver, the AOX staining was somewhat diffuse surrounding the lipid droplets (Fig. 7H, inset). These observations clearly establish that the induction of many of the PPAR{alpha} target genes can occur independently of peroxisome proliferation and that peroxisome proliferation in rodent liver is highly correlatable with the induction mostly of the L-PBE gene and to D-PBE gene to a lesser extent (Fig. 6).



View larger version (76K):
[in this window]
[in a new window]
  		FIG. 6.
Induction of L-PBE in liver. A, liver proteins analyzed by SDS-PAGE for the induction of L-PBE (78-kDa protein) with PPAR{alpha} activation and peroxisome proliferation by Wy-14,643, a synthetic peroxisome proliferator (lane 2, wild type (WT); lane 6, D-PBE-/-) or occurring spontaneously in AOX-/- mouse (lane 8). Lack of L-PBE induction in the liver of L-PBE-/- mouse that was treated with Wy-14,643 and in DKO mouse liver, which manifests spontaneous induction of PPAR{alpha} target genes in the absence of spontaneous peroxisome proliferation, suggests strong correlation between L-PBE induction and peroxisome proliferation and indicates that PPAR{alpha} target genes can be up-regulated in the absence of peroxisome proliferation. SDS-PAGE of total liver protein (50 µg) from wild-type (lanes 1 and 2), L-PBE-/- (lanes 3 and 4), D-PBE-/- (lanes 5 and 6), L-PBE-/-D-PBE-/- double nulls (DKO) (lane 7), and AOX-/- (lane 8) mice is shown. + indicates Wy-14,643-treated, - indicates untreated. Liver homogenates were stained with Coomassie Brilliant R Blue. B, immunoblot with L-PBE antibody. Samples (20 µg of protein) were electrophoresed (as in panel A), transferred to a membrane, and immunoblotted to detect L-PBE. The 78-kDa protein seen in panel A is identified as L-PBE.

 



View larger version (139K):
[in this window]
[in a new window]
  		FIG. 7.
Immunohistochemical staining for L-PBE and AOX in the liver. A–D represent L-PBE immunohistochemical staining, and E–H, represent AOX staining. A and E, wild type; B and F, wild type fed Wy-14,643 for 2 weeks; C and G, AOX-/-; and D and H, L-PBE-/-D-PBE-/- mice. The inset in F shows high magnification to depict granularity consistent with peroxisome proliferation, and the inset in H shows diffuse staining decorating lipid droplets.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Peroxisomes are single-membrane bound organelles that are present in all eukaryotic cells. These organelles contain many enzyme systems responsible for a wide variety of metabolic functions, including the {beta}-oxidation of very long-chain fatty acids (1, 2, 4). Abnormalities of peroxisomal fatty acid {beta}-oxidation and absence or reduction in the number of peroxisomes in cells play a significant role in the pathophysiological manifestations of Zellweger syndrome and other peroxisome biogenesis disorders (1, 2, 24, 32, 33). Also important is that the induction in liver of enzymes involved in the classical {beta}-oxidation system and profound increases in peroxisome population in liver cells caused by structurally diverse peroxisome proliferators has been associated with the development of liver cancer in rats and mice, and these effects are regulated by the nuclear receptor PPAR{alpha} (1, 6, 7, 10, 14, 34). Thus, increases and decreases in fatty acid oxidation and peroxisome population appear to be detrimental to health (1).

Evidence from gene knockout mouse models of peroxisomal proteins points to the role, in particular, of peroxisomal {beta}-oxidation system in preventing the accumulation of toxic peroxisomal {beta}-oxidation substrates that appear to function as PPAR{alpha} ligands. This scenario is vividly exhibited in the liver of AOX-/- mouse in that absence of AOX, the first and rate-limiting enzyme of the classical {beta}-oxidation pathway, leads to sustained PPAR{alpha} activation with induction of PPAR{alpha}-regulated target genes, spontaneous peroxisome proliferation, and the eventual development of hepatocellular carcinomas, implying that unmetabolized substrates of AOX function as PPAR{alpha} ligands (15, 25). The mouse model of disruption of the L-PBE gene further supported the assumption that AOX substrates function as PPAR{alpha} ligands because L-PBE-/- mouse livers revealed no such increases in peroxisome number and no up-regulation of PPAR{alpha} target genes in liver (16). However, there is uncertainty in that straight-chain enoyl-CoAs generated by AOX may crossover to be metabolically degraded by D-PBE, the second enzyme of the noninducible peroxisomal {beta}-oxidation pathway (16). Although D-PBE-/- mouse corroborated this hypothesis to a certain extent (18), it appeared necessary to examine the role of disruption of the metabolism of enoyl-CoAs in the activation of PPAR{alpha} in liver by generating L-PBE-/-D-PBE-/- DKO mice because these mice have a complete block in peroxisomal {beta}-oxidation at the level of L- and D-bifunctional enzymes as these genes are disrupted, resulting in the absence of these mRNAs and proteins in their livers (Figs. 4, 5). Mouse embryonic skin fibroblasts obtained from L-PBE-/-D-PBE-/- mice showed defects in the degradation of lignoceric acid and 2-metyhlhexadecanoic acid, indicating that in these DKO mice, peroxisomal degradation is completely blocked (35). Although in the present study we did not directly assess the peroxisomal and mitochondrial {beta}-oxidation activities in the livers of DKO mice, the accumulation of very long-chain fatty acids and the data on embryonic fibroblasts clearly establish the complete block of peroxisomal {beta}-oxidation in these animals. Furthermore, in the mouse and human genome, only two bifunctional {beta}-oxidation genes (L- and D-PBE) have been identified, and the disruption of both these genes in our DKO mice ensures blockage of peroxisomal fatty acid oxidation at the level of the second enzyme. The present study demonstrates that absence of both bifunctional enzymes in L-PBE-/-D-PBE-/- mice leads to intrauterine and postnatal growth retardation with death occurring predominantly during early postnatal phase. Mice that survive beyond the first week of life develop severe hypotonia, fail to feed properly, become growth-retarded, and do not survive weaning. Thus, although knockout of either the L-PBE gene or the D-PBE gene is compatible with life, the disruption of both these genes in the same animal leads to lethal outcome by weaning age. Although these double knockout mice do not exhibit any anatomical defects in neuronal migration, the functional inactivity of nervous system caused by unmetabolized toxic substrates of {beta}-oxidation cannot be excluded (35). Evidence clearly suggests that the interruption at the second step of the fatty acid oxidation catalyzed by the inducible and noninducible pathways leads to alterations in hepatic mitochondrial structure, reminiscent of changes occurring in Zellweger patients and some mouse models for disturbances in peroxisome biogenesis (24, 36). In aggregate, microvesicular steatosis, paucity of peroxisomes and mitochondrial abnormalities encountered in L-PBE-/-D-PBE-/- mouse liver mimic changes described in Zellweger patients, and this is most likely related to the combined bifunctional enzyme deficiency and total interruption of fatty acid oxidation at the enoyl-CoA level.

Of considerable interest is that this study presents evidence for the up-regulation of PPAR{alpha} target genes in liver in the absence of the morphological phenomenon of peroxisome proliferation. In L-PBE-/-D-PBE-/- mouse liver, increases in the hepatic AOX, PTL, CYP4A1, CYP4A3, and ACTE mRNA levels (Fig. 4A) were evident, and these are known PPAR{alpha} target genes (3, 6, 34, 37, 38). Increases in PEX11{alpha} and PMP70 mRNA levels were also observed. PEX11{alpha} has been shown to be dispensable for PPAR{alpha}-mediated peroxisome proliferation, although overexpression of this peroxin is known to enhance peroxisome formation (32, 33). Increases in PEX11{alpha} mRNA in the absence of peroxisome proliferation in L-PBE-/-D-PBE-/- mouse liver may appear paradoxical, but it provides an indication of PPAR{alpha} activation. Overexpression of other putative PPAR{alpha}-regulated genes such as macrophage scavenger receptor CD36 (37, 39), Ly-6D (19, 40), pyruvate dehydrogenase kinase protein (PDK4) (41), SCP2/SCPx (19, 27, 28, 42), SHLR (uncharacterized endogenous virus-like sequence) (43), mLipase (44), and others (19) in the liver of these double nulls is further indication of PPAR{alpha} activation by natural ligands that are unmetabolized substrates of peroxisomal {beta}-oxidation. Although fatty acids are generally considered to be PPAR{alpha} ligands (45, 46), we entertain the possibility that very long-chain acyl-CoAs (>20 C) or acyl-carnitines in AOX-/- mice and very-long-chain enoyl-CoAs in L-PBE-/-D-PBE-/- mice can act as PPAR{alpha} ligands, and these possibilities should be properly evaluated. Since acyl-CoAs enter peroxisomes, they can also exit peroxisomes by diffusion or transported out as acyl-carnitines. Although the possibility that acyl-CoAs can be reconverted or hydrolyzed to free fatty acids by peroxisomal thioesterases (ACTE) (38) and that enoyl-CoAs can be used by 2-enoyl-CoA reductatse and be converted to acyl-CoAs (47) exists, this is considered futile because it wastes NADPH. It is possible that in these double null mice, under limiting peroxisomal NADPH concentration, there will be increases in the concentration of cellular enoyl-CoAs, which may diffuse out of peroxisomes to act as PPAR{alpha} ligands. Evidence also suggests that phytanic acid activates PPAR{alpha} in SCPx-deficient mice (48), and consistent with this is the increased levels of phytanic acid in the serum of L-PBE-/-D-PBE-/- mice. These knockout models of peroxisomal {beta}-oxidation raise the question that different endogenous ligands generated during very long-chain fatty acid oxidation can serve as PPAR{alpha} ligands. Additional studies are needed to analyze the amounts and composition of acyl-CoAs, acyl-carnitines, and enoyl-CoAs in AOX-/- and L-PBE-/-D-PBE-/- mice.

These studies also indicate that PPAR{alpha} target gene overexpression can occur in the absence of peroxisome proliferation and that these two events can be dissociable. Studies with a variety of structurally diverse synthetic peroxisome proliferators have unequivocally established a strong correlation between hepatic peroxisome proliferation, PPAR{alpha} target gene overexpression, and the development of liver cancer in rats and mice (5, 6, 7, 14, 49). Sustained activation of PPAR{alpha} and spontaneous peroxisome proliferation in the liver of AOX-/- mouse also lead to the development of liver tumors after 12 months of age (15). Although PPAR{alpha} activation was seen in L-PBE-/- D-PBE-/- mouse livers, these mice did not survive long enough to develop liver tumors. It is argued that the carcinogenic risk to humans of chronic exposure to these PPAR{alpha} ligands is negligible to nonexistent because peroxisome proliferation is not profound in human hepatic cells studied mostly in cell culture (50–53). The present study establishes unequivocally that absence of peroxisome proliferation does not necessarily imply the total negation of the global PPAR{alpha} target gene-activating effects of synthetic or endogenous peroxisome proliferators (endogenous/biological ligands of this receptor). Our data strongly suggest that in the mouse, the morphological parameter of peroxisome proliferation is a reflection mostly of the L-PBE gene transcriptional activity (13, 54), and to a lesser extent of D-PBE induction (16, 55). In the rodent, the peroxisome proliferator-response element of L-PBE gene binds one or two PPAR-retinoid X receptor heterodimers, providing the peroxisome poliferator signaling pathway with two levels of response (13, 54). The paucity of peroxisomes in liver cells of L-PBE-/-D-PBE-/- mice is reminiscent of that noted in AOX-/- hepatocytes with microvesicular steatosis (17). The excess accumulation of potentially toxic very long-chain fatty acid metabolites may interfere with import of proteins into the peroxisome matrix for organelle formation (17, 31). The morphological abnormalities in liver of in L-PBE-/-D-PBE-/- liver cells and marked reduction in the processing of AOX and of SCPx proteins (Fig. 5) are reminiscent of changes described in certain Zellweger syndrome patients (29, 30, 56). The near absence of UOX protein in DKO livers also suggests that peroxisomal proteins are not appropriately targeted to the peroxisome (17, 31). Immunohistochemical staining for AOX shows increased staining in DKO livers, but unlike in wild-type mice fed Wy-14,643, the staining is not granular (peroxisomal) but somewhat diffuse in the cytoplasm. Because of the disruption of branched chain fatty acid oxidation system in the L-PBE-/-D-PBE-/- mice, it is likely that these animals may have abnormalities in bile acid metabolism (57) in addition to defects in the metabolism of very long-chain fatty acids.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grants GM23750 (to J. K. R.) and CA84472 (to M. S. R.) and by Fonds Wetenschappelijk Onderzoek Vlaanderen G 0235 01, Geconcerteerde Onderzoeksacties GOA/99/-09 and European Community Grant QLG1-CT2001-01299 (to M. B. and P. V. V.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

|| To whom correspondence should be addressed:Dept. of pathology, Northwestern University, Feinberg School of Medicine, 303 East Chicago Ave., Chicago, IL 60611-3008. Tel.: 312-505-8144; Fax: 312-503-8249; E-mail: jkreddy{at}northwestern.edu.

1 The abbreviations used are: AOX, peroxisomal fatty acyl-CoA oxidase; PPAR, peroxisome proliferator-activated receptor; RXR, retinoidx-receptor for 9-cis-retinoic acid; L-PBE, enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenease bi- (multi) functional enzyme; D-PBE, D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bi- (multi) functional enzyme; DKO, L-PBE-/-D-PBE-/- double null mice; PTL, peroxisomal thiolase; SCP2/SCPx, sterol carrier protein 2, sterol carrier protein X; CYP4A1 and CYP4A3, encode microsomal cytochrome P450 fatty acid {omega}-hydroxylase; ACTE, acyl-CoA thioesterase PTE-2; UOX, urate oxidase; CTL, catalase; PEX11{alpha}, peroxin-peroxisome membrane protein; PMP70, 70-kDa peroxisomal membrane protein; CD36, cluster of differentiation 36; SHLR, endogenous virus-like sequence; PDK-4, pyruvate dehydrogenase kinase protein; C3f, gene-rich cluster C3f; Ly-6D, lymphocyte antigen 6 complex locus D; mLipase, monoglyceride lipase. Back


   ACKNOWLEDGMENTS
 
We thank Drs. Amiya K. Hajra and Stefan Alexson for helpful discussion.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Reddy, J. K., and Hashimoto, T. (2001) Annu. Rev. Nutr. 21, 193-230[CrossRef][Medline] [Order article via Infotrieve]
  2. Wanders, R. J. A., Vreken, P., Ferdinandusse, S., Jansen, G. A., Waterham, H. R., Van Roermund, C. W. T., and Van Grunsven, E. G. (2001) Biochem. Soc. Trans. 29, 250-267[CrossRef][Medline] [Order article via Infotrieve]
  3. Johnson, E. F., Palmer, C. N. A., Griffin, K. J., and Hsu, M.-H. (1996) FASEB J. 10, 1241-1248[Abstract]
  4. Hashimoto, T. (1999) Neurochem. Res. 24, 551-5663[CrossRef][Medline] [Order article via Infotrieve]
  5. Reddy, J. K., and Krishnakantha, T. P. (1975) Science 190, 787-789[Abstract/Free Full Text]
  6. Reddy, J. K., and Chu, R. (1996) Ann. N. Y. Acad. Sci. 804, 176-201[Medline] [Order article via Infotrieve]
  7. Reddy, J. K., Hignite, C. E., and Azarnoff, D. L. (1980) Nature 283, 397-398[CrossRef][Medline] [Order article via Infotrieve]
  8. Seedorf, U., Raabe, M., Ellinghaus, P., Kannenberg, F. Fobker, M., Engel, T., Denis, S., Wouters, F., Wirtz, K. W. A., Wanders, R. J. A., Maeda, N., and Assmann, G. (1998) Genes Dev. 12, 1189-1201[Abstract/Free Full Text]
  9. Reddy, J. K., Goel, S. K., Nemali, M. R., Carrino, J. J., Laffler, T. G., Reddy, M. K., Sperbeck, S. J., Osumi, T., Hashimoto, T., Lalwani, N. D., and Rao, M. S. (1986) Proc. Natl. Scad. Sci. U. S. A. 83, 747-1751[Abstract/Free Full Text]
  10. Issemann, J., and Green, S. (1990) Nature 347, 645-650[CrossRef][Medline] [Order article via Infotrieve]
  11. Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., and Wahli, W. (1992) Cell 68, 879-887[CrossRef][Medline] [Order article via Infotrieve]
  12. Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., and Evans, R. M. (1992) Nature 358, 771-774[CrossRef][Medline] [Order article via Infotrieve]
  13. Zhang, B., Marcus, S. L., Sajjadi, F. H., Alvares, K., Reddy, J. K., Subramani, S., Rachubinski, R. A., and Capone, J. P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7541-7545[Abstract/Free Full Text]
  14. Gonzalez, F. J. Peters, J. M., and Cattley, R. C. (1998) J. Natl. Cancer Inst. 90, 1702-1709[Abstract/Free Full Text]
  15. Fan, C. Y., Pan, J., Usuda, N., Yeldandi, A. V., Rao, M. S., and Reddy, J. K. (1998) J. Biol. Chem. 273, 15639-15645[Abstract/Free Full Text]
  16. Qi, C., Zhu, Y., Pan, J., Usuda, N., Maeda, N., Yeldandi, A. V., Rao, M. S., Hashimoto, T., and Reddy, J. K. (1999) J. Biol. Chem. 274, 15775-15780[Abstract/Free Full Text]
  17. Fan, C.-Y., Pan, J., Chu, R., Lee, D., Kluckman, K. D., Usuda, N., Singh, L., Yeldandi, A. V., Rao, M. S., Maeda, N., and Reddy, J. K. (1996) J. Biol. Chem. 271, 24698-24710[Abstract/Free Full Text]
  18. Baes, M., Huyghe, S., Carmeliet, P., Declercq, P. E., Collen, D., Mannaerts, G. P., and Van Veldhoven, P. P. (2000) J. Biol. Chem. 275, 16329-16336[Abstract/Free Full Text]
  19. Cherkaoui-Malki, M., Meyer, K., Cao, W.-Q., Latruffe, N., Yeldandi, A. V., Rao, M. S., Bradfield, C. A., and Reddy, J. K. (2001) Gene Expr. 9, 291-304[Medline] [Order article via Infotrieve]
  20. Reddy, J. K., and Kumar, N. S. (1977) Biochem. Biophys. Res. Commun. 77, 824-829[CrossRef][Medline] [Order article via Infotrieve]
  21. Aoyama, T., Peters, J. M., Iritani, N., Nakajima, T., Furihata, K., Hashimoto, T., and Gonzalez, F. J. (1998) J. Biol. Chem. 273, 5678-5684[Abstract/Free Full Text]
  22. Hashimoto, T., Fujita, T., Usuda, N., Cook, W., Qi, C., Peters, J. M., Gonzalez, F. J., Yeldandi, A. V., Rao, M. S., and Reddy, J. K. (1999) J. Biol. Chem. 274, 19228-19236[Abstract/Free Full Text]
  23. Takemoto, Y., Suzuki, Y., Horibe, R., Shimozawa, N., Wanders, R. J. A., and Kondo, N. (2003) Brain Dev. 27, 481-487
  24. Baumgart, E., Vanhorebeek, I., Grabenbauer, M., Borgers, M., Declercq, P. E., Fahimi, H. D., and Baes, M. (2001) Am. J. Pathol. 159, 1477-1494[Abstract/Free Full Text]
  25. Yeldandi, A. V., Rao, M. S., and Reddy, J. K. (2000) Mutat. Res. 448, 159-177[Medline] [Order article via Infotrieve]
  26. Meyer, K., Lee, J-S., Dyck, P. A., Cao, W-Q., Rao, M. S., Thorgeirsson, S., and Reddy, J. K. (2003) Carcinogenesis 24, 975-984[Abstract/Free Full Text]
  27. Mammalian Gene Collection (MGC) Program Team (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 16899-16903[Abstract/Free Full Text]
  28. Lopez, D., Irby, R. B., and McLean, M. P. (2003) Mol. Cell. Endocrinol. 205, 169-184[CrossRef][Medline] [Order article via Infotrieve]
  29. Hashimoto, T. (1996) Ann. N. Y. Acad. Sci. 804, 86-98[Medline] [Order article via Infotrieve]
  30. Chu, R., Varanasi, U., Chu, S., Lin, Y., Usuda, N., Rao, M. S., and Reddy, J. K. (1995) J. Biol. Chem. 270, 4908-4915[Abstract/Free Full Text]
  31. Subramani, S., Koller, A., and Snyder, W. B. (2000) Annu. Rev. Biochem. 69, 399-418[CrossRef][Medline] [Order article via Infotrieve]
  32. Li, X., Baumgart, E., Morrell, J. C., Jiminez-Sanchez, G., Valle, D., and Gould, S. J. (2002) Mol. Cell. Biol. 22, 4358-4435[Abstract/Free Full Text]
  33. Li, X., Baumgart, E., Dong, G-X., Morrell, J. C., Jiminez-Sanchez, G., Valle, D., Smith, K. D., and Gould, S. J. (2002) Mol. Cell. Biol. 22, 8226-8240[Abstract/Free Full Text]
  34. Lee, S. S.-T, Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., and Gonzalez, F. J. (1995) Mol. Cell. Biol. 15, 3012-3022[Abstract]
  35. Baes, M., Gressens, P., Huyghe, S., De Nys, K., Qi, C., Jia, Y., Mannaerts, G. P., Evrard, P., Van Veldhoven, P. P., Declercq, P. E., and Reddy, J. K. (2002) J. Neuropathol. Exp. Neurol. 61, 368-374[Medline] [Order article via Infotrieve]
  36. Goldfischer, S., Moore, C. L., Johnson, A. B., Spiro, A. J., Valsamis, M. P., Wisniewski, H. K., Ritch, R. H., Norton, W. T., Rapin, I., and Gartner, L. M. (1973) Science 182, 62-64[Abstract/Free Full Text]
  37. Desvegne, B., and Wahli, W. (1999) Endocr. Rev. 20, 649-650[Abstract/Free Full Text]
  38. Hunt, M. C., Solaas, K., Kase, B. F., and Alexson, S. E. H. (2002) J. Biol. Chem. 277, 1128-1138[Abstract/Free Full Text]
  39. Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B. Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H. B., Fruchart, J. C., Clavey, V., and Staeles, B. (2001) Nat. Med. 7, 53-57[CrossRef][Medline] [Order article via Infotrieve]
  40. Dadras, S. S., Cook, W. S., Yeldandi, A. V., Cao, W-Q., Rao, M. S., Wang, Z., and Reddy, J. K. (2000) Gene Expr. 9, 173-181
  41. Way, M., Harrington, W. W., Brown, K. K., Gottschalk, W. K., Sundseth, S. S., Mansfield, T. A., Ramachandran, R. K., Willson, T. M., and Kliewer, S. A. (2001) Endocrinology 142, 1269-1277[Abstract/Free Full Text]
  42. Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh, M., Konno, H., Okazaki, Y., Muramatsu, M., and Hayashizaki, Y. (2000) Genome Res. 10, 1617-1630[Abstract/Free Full Text]
  43. Panozzo, J., Bertoncini, D., Miller, D., Libertin, C. R., and Woloschalk, G. E. (1991) Carcinogenesis 12, 801-804[Abstract/Free Full Text]
  44. Karlsson, M., Contreras, J. A., Hellman, U., Tronqvist, H., and Holm, C. (1997) J. Biol. Chem. 272, 27218-27223[Abstract/Free Full Text]
  45. Gottlicher, M., Widmark, E., Li, Q., and Gustafsson, J. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 453-457[Abstract/Free Full Text]
  46. Forman, B. M., Chen, J. C., and Evans, R. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4312-4317[Abstract/Free Full Text]
  47. Das, A. K., Uhler, M. D., and Hajra, A. K. (2000) J. Biol. Chem. 275, 24333-24340 48[Abstract/Free Full Text]
  48. Ellinghaus, p., Wolfram, C., Assmann, G., Spencer, F., and Seedorf, U. (1999) J. Biol. Chem. 274, 2766-2772[Abstract/Free Full Text]
  49. Rao, M. S., and Reddy, J. K. (1996) Ann. N. Y. Acad. Sci. 804, 573-587[Medline] [Order article via Infotrieve]
  50. Corton, J. C., Anderson, S. P., and Stauber, A. (2000) Annu. Rev. Pharmacol. Toxicol. 40, 491-518[CrossRef][Medline] [Order article via Infotrieve]
  51. Elcombe, C. R., Bell, D. R., Elias, E., Hasmall, S. C., and Plant, N. J. (1996) Ann. N. Y. Acad. Sci. 804, 628-635[Medline] [Order article via Infotrieve]
  52. Hsu, M.-H., Savas, U., Griffin, K. J., and Johnson, E. F. (2001) J. Biol. Chem. 276, 27950-27958[Abstract/Free Full Text]
  53. Yu, S., Cao, W. Q., Kashireddy, P., Meyer, K., Jia, Y., Hughes, D. E., Tan, Y., Feng, J., Yeldandi, A. V., Rao, M. S, Costa, R. H., Gonzalez, F. J., and Reddy, J. K. (2001) J. Biol. Chem. 276, 42485-42491[Abstract/Free Full Text]
  54. Chu, R., Lin, Y., Rao, M. S., and Reddy, J. K. (1995) J. Biol. Chem. 50, 29636-29639
  55. Fan, L.-Q., Cattley, R. C., and Corton, J. C. (1998) J. Endocrinol. 158, 237-246[Abstract]
  56. Ferdinandusse, S., Denis, S., van Berkel, E., Dacremont, G., and Wanders, R. J. A. (2000) J. Lipid Res. 41, 336-342[Abstract/Free Full Text]
  57. Russell, D. W. (2003) Annu. Rev. Biochem. 72, 137-174[Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Physiol. GenomicsHome page
M. Bunger, H. M. van den Bosch, J. van der Meijde, S. Kersten, G. J. E. J. Hooiveld, and M. Muller
Genome-wide analysis of PPAR{alpha} activation in murine small intestine
Physiol Genomics, July 18, 2007; 30(2): 192 - 204.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Huyghe, H. Schmalbruch, K. De Gendt, G. Verhoeven, F. Guillou, P. P. Van Veldhoven, and M. Baes
Peroxisomal Multifunctional Protein 2 Is Essential for Lipid Homeostasis in Sertoli Cells and Male Fertility in Mice
Endocrinology, May 1, 2006; 147(5): 2228 - 2236.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Ferdinandusse, S. Denis, H. Overmars, L. Van Eeckhoudt, P. P. Van Veldhoven, M. Duran, R. J. A. Wanders, and M. Baes
Developmental Changes of Bile Acid Composition and Conjugation in L- and D-Bifunctional Protein Single and Double Knockout Mice
J. Biol. Chem., May 13, 2005; 280(19): 18658 - 18666.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. A. Hostetler, A. D. Petrescu, A. B. Kier, and F. Schroeder
Peroxisome Proliferator-activated Receptor {alpha} Interacts with High Affinity and Is Conformationally Responsive to Endogenous Ligands
J. Biol. Chem., May 13, 2005; 280(19): 18667 - 18682.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. K. Reddy
Peroxisome Proliferators and Peroxisome Proliferator-Activated Receptor {alpha}: Biotic and Xenobiotic Sensing
Am. J. Pathol., June 1, 2004; 164(6): 2305 - 2321.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/47/47232    most recent
M306363200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jia, Y.
Right arrow Articles by Reddy, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jia, Y.
Right arrow Articles by Reddy, J. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement